Genetic Technologies Limited
GENE
$0.765
-$0.015-1.92%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 12.21% | 14.38% | -16.50% | -12.56% | -80.94% |
| Total Depreciation and Amortization | -27.57% | -29.39% | -15.75% | -18.60% | 8.84% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -121.48% | -120.96% | 310.38% | 303.30% | 102.33% |
| Change in Net Operating Assets | 168.32% | 166.62% | -- | -- | -333.98% |
| Cash from Operations | -55.67% | -51.84% | 35.17% | 37.35% | -120.46% |
| Capital Expenditure | 66.67% | 67.35% | -820.00% | -736.36% | 18.64% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | 100.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -73.80% | -74.67% | 46.95% | 41.76% | 1,138.89% |
| Cash from Investing | -74.85% | -75.45% | 121.75% | 121.07% | 410.48% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -3.53% | -3.53% | -3.85% | -3.85% | 32.86% |
| Issuance of Common Stock | -64.07% | -64.07% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 99.50% | 99.50% | -- | -- | -8,707.69% |
| Cash from Financing | -51.42% | -52.62% | -4.39% | -0.70% | 2,258.07% |
| Foreign Exchange rate Adjustments | -129.49% | -128.67% | -215.49% | -210.81% | 401.41% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -195.23% | -192.88% | 38.91% | 40.97% | 247.66% |
